ERBB2 and breast cancer: Also in breast cancer, CAFs influence responses to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) therapies (e.g., trastuzumab) by increasing cancer stem cell populations and activating IL–6-mediated Signal Transducer and Activator of Transcription 3/Phosphoinositide 3-Kinase (STAT3/PI3K) pathways [167].